Total Voting Rights & Block Listing Return

RNS Number : 9342D

Ergomed plc

01 July 2019

 

 PRESS RELEASE

Date: 1 July 2019

Ergomed plc

TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN

Total Voting Rights

In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 30 June 2019 consisted of 46,717,412 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

Block Listing Six Monthly Return

Name of applicant:		Ergomed plc
Name of scheme:		Ergomed plc Long Term Incentive Plan
Period of return:	From:	1 January 2019	To:	30 June 2019
Balance of unallotted securities under scheme(s) from previous return:		1,745,000
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		542,164
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		1,202,836
Number and class of securities originally admitted and the date of admission		1,800,000 ordinary shares of 1p each - 2 July 2018
Total number of securities in issue at the end of the period		46,717,412 ordinary shares of 1p each

Name of contact:	Nick Blech - Deputy CFO
Telephone number of contact:	[phone]

 Enquiries:

Ergomed plc	Tel: [phone]
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott Matthew Neal / Olivia Manser	[e-mail]
MC-Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 

END

 

 

MSCSDFEFSFUSELM